Table 1.
Baseline characteristics of all enrolled patients (N = 44).
Fig 1.
Overview of patient enrollment, clinical follow-up and personalized ctDNA analysis.
Fig 2.
Circulating tumor DNA can detect relapse earlier than CA125 and CT scan imaging.
In this representative example, increases in ctDNA levels in Patient 137 levels precede a rise in CA-125 levels by six months and pre-date positive identification of tumor growth requiring bowel resection seven months later. CT scanning was non-specific and patient was brought to the operating room for exploratory surgery, which revealed the presence of tumor.
Table 2.
Levels of ctDNA correlate with tumor presence and are as sensitive and specific as CA-125.
Fig 3.
Undetectable levels of ctDNA following initial treatment are associated with improved survival.
Kaplan–Meier analysis of progression-free (left panel) and overall survival (right panel) between individuals with undetectable (ctDNA = 0; blue lines) and detectable ctDNA (≥ 1; red lines). Significant differences in progression-free survival (p = 0.001) and overall survival (p = 0.0194) between undetectable and detectable groups.
Table 3.
Serial measurement of pre- and post-treatment ctDNA for predicting survival.